Furthermore, the targeted delivery of Axitinib, which inhibits several isoforms of VEGFR, led to a reduction in the Treg population, which unleashed T-cell-mediated antitumor immunity and enhanced melanoma tumor growth inhibition. The gene discussed is KDR; the disease is neoplasm.